Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2023-06-21 00:00:00 ET · period of report 2023-06-09 · accession 0001104659-23-073212 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-06-21	2023-06-09	LGND	Sabba Stephen L	Dir	A - Grant	$0.00	+1,142	26.9K	+4%	$0
D	2023-06-21	2023-06-09	LGND	Sabba Stephen L	Dir	A - Grant	$0.00	-5,461	5,461	-50%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-06-09	A	A	1,142	$0.00	26,926	D	—	—	(F1) These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
2	Derivative	Non-Qualified Stock Option (right to buy)	2023-06-09	A	D	5,461	$0.00	5,461	D	$73.76 · — to 2033-06-09	5,461 Common Stock	(F2) These securities, as represented in Column 5, were acquired by a grant of 5,461 shares approved by the Board of Directors of the Company at the 2023 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.